CDNACareDx, Inc.

1. Sep 16, 2026On July 7, 2026, CareDx, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission (the “SEC”) reporting the completion of its acquisition of Naveris, Inc., a Delaware corporation (“Naveris”)Acquisition or disposition completed · Form 8-K/A
2. Jul 7, 2026Eurobio Transaction On June 30, 2026, CareDx, Inc. (the “Company”) completed the previously announced sale of the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software to Eurobio Scientific S.A. …Acquisition or disposition completed · Form 8-K
3. Jun 15, 2026On June 11, 2026, CareDx, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
4. Apr 28, 2026On April 28, 2026, CareDx, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Naveris, Inc., a Delaware corporation (“Naveris”), Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Shareholder Representative …Material agreement entered · Form 8-K
5. Apr 23, 2026The Original Report otherwise remains unchanged.Director or officer change · Form 8-K/A
6. Apr 16, 2026On April 15, 2026, CareDx, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Eurobio Scientific S.A. (“Eurobio”), pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell to Eurobio the shares of CareDx AB, a wholly-owned Swedish …Material agreement entered · Form 8-K
7. Feb 25, 2026The Board of Directors of the Company has appointed Keith Kennedy as the Company’s Chief Financial Officer and Chief Operating Officer, effective as of February 26, 2026.Earnings release · Form 8-K/A
8. Dec 18, 2025On September 26, 2025, an unopposed motion for the preliminary approval of settlement was filed after CareDx, Inc. (the “Company”) reached an agreement in principle for a proposed settlement (the “Proposed Settlement”) of a shareholder derivative litigation, captioned Edelman, et al., v.Other event · Form 8-K
9. Dec 15, 2025On December 12, 2025, the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) amended and restated the Company’s bylaws (the “Amended and Restated Bylaws”) to change the voting standard for the election of directors from a plurality to a majority voting standard, except in a contested election, where a …Charter/bylaw amendment or fiscal-year change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.